Continuing discussion on advanced renal cell carcinoma, Robert J. Motzer, MD, reviews recent clinical trial data presented at ASCO 2023 and KCRS 2023.
Transcript:
Robert J. Motzer, MD: The KEYNOTE-426 update was presented at ASCO [American Society of Clinical Oncology Annual Meeting], as well. This was the first of the TKI-IO [tyrosine kinase inhibitor/immuno-oncology] combinations to be compared with sunitinib and demonstrate a higher level of efficacy. It serves as proof of principle for the approach of a TKI-IO in first-line therapy for [renal cell carcinoma]. And [because] it was the first study that was reported, it’s subject to the longest follow-up. It likewise demonstrated a durable effect for axitinib plus pembrolizumab, and generally manageable safety program over the course of the patient’s [treatment]. This was confirmatory to me in terms of the initial results for the KEYNOTE-426 that were reported a few years back and establishes this as an acceptable standard option in first-line therapy.
At ASCO and KCRS [Kidney Cancer Research Summit], the updated data from the CLEAR trial [NCT02811861] and the KEYNOTE trial were really the lead contenders in terms of first-line therapy. [At KCRS], there was also longer follow-up of the Study 111 trial [NCT02501096], which was a phase 1/2 study of lenvatinib plus pembrolizumab that was conducted in different groups based on prior treatment and a treatment-naïve group in patients who had progressed on a [TKI] and progressed on an IO. That was presented by Chung-Han Lee, MD, PhD, from Memorial Sloan Kettering Cancer Center, and likewise favored the durability of the regimen over time and, in general, the tolerability in patients who were treated on that trial regardless of their prior line of therapy.
Transcript is AI-generated and edited for clarity and readability.
Key Takeaways From QOL and Use of Steroids With IO-Based RCC Regimens
May 6th 2024During a Case-Based Roundtable® event, Ulka Vaishampayan, MBBS, discussed the safety and quality-of-life data for ipilimumab plus nivolumab in patients with advanced renal cell carcinoma in the second article of a 2-part series.
Read More
Enhancing Precision in Immunotherapy: CD8 PET-Avidity in RCC
March 1st 2024In this episode of Emerging Experts, Peter Zang, MD, highlights research on baseline CD8 lymph node avidity with 89-Zr-crefmirlimab for the treatment of patients with metastatic renal cell carcinoma and response to immunotherapy.
Listen
Comparing Choices for IO/TKI Combinations in Advanced RCC
May 2nd 2024During a Case-Based Roundtable® event, Shilpa Gupta, MD, led a discussion on the combination of immunotherapy and tyrosine kinase inhibitors for patients with advanced renal cell carcinoma in the second article of a 2-part series.
Read More
Beyond the First-Line: Economides on Advancing Therapies in RCC
February 1st 2024In our 4th episode of Emerging Experts, Minas P. Economides, MD, unveils the challenges and opportunities for renal cell carcinoma treatment, focusing on the lack of therapies available in the second-line setting.
Listen
Sustained Treatment-Free Survival in RCC Seen With Nivolumab and Ipilimumab
April 30th 2024Nivolumab monotherapy plus salvage nivolumab/ipilimumab demonstrated superior treatment-free survival rates among patients with advanced renal cell carcinoma, especially in patients with favorable risk profiles.
Read More
Roundtable Roundup April: Renal Cell Carcinoma
April 27th 2024In separate, live virtual events, Arnab Basu, MD, MPH, and Robert J. Motzer, MD, asked participants which therapy they would choose for a patient with clear cell renal cell carcinoma (RCC) and why they would make that choice.
Read More